Connie Ding Email

VP, Head Legal Department . WUXI BIOLOGICS

Wuxi,

Location

LinkedIn

Current Roles

Employees:
3309
Revenue:
$665.1M
About
Our Vision: “Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore exceeding 280,000 liters after 2023, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network. As of June 30, 2020, there were a total of 286 integrated projects , including 141 projects in pre-clinical development stage, 125 projects in early-phase (phase I and II) clinical development, 19 projects in late-phase (phase III) development and one project in commercial manufacturing.
WUXI BIOLOGICS Address
411 Swedeland Rd
Wuxi, null
WUXI BIOLOGICS Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.